Expanded Access Study of Phage Treatment in Covid-19 Patients on Anti-Microbials for Pneumonia or Bacteremia/Septicemia Due to A. Baumannii, P. Aeruginosa or S. Aureus

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Dec 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bacteriophage therapeutics-BiomX (Primary)
Indications Acinetobacter infections; Bacteraemia; COVID-19 pneumonia; Pseudomonal infections; Septicaemia; Staphylococcal infections
Focus Expanded access; Therapeutic Use
Sponsors Adaptive Phage Therapeutics

06 Dec 2021 Status changed from recruiting to completed.
26 Nov 2020 New trial record
18 Nov 2020 According to an Adaptive Phage Therapeutics media release, Expanded Access IND for PhageBank has been clearance by the U.S. Food and Drug Administration (FDA).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com